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Following the current hypothesis that acute schizophrenic psychotic
illness is associated with a striatal ‘hyperdopaminergic state’, presynaptic
integrity and dopamine transporter (DAT) density in first-episode,
neuroleptic-naive schizophrenic patients was measured by single-photon-
emission-tomography (SPECT) and compared with that in healthy control
subjects. A new SPECT-ligand for assessment of the striatal DAT, the
Technetium-99m-labelled tropane TRODAT-1 ([99mTc]TRODAT-1), was used.
Ten inpatients suffering from a first acute schizophrenic episode and 10
age- and sex-matched healthy control subjects underwent SPECT with
[99mTc]TRODAT-1. On the day of SPECT, psychopathological ratings were
performed with the Brief Psychiatric Rating Scale (BPRS), the Positive
and Negative Syndrome Scale (PANSS) and Schedule for Assessment of
Negative Symptoms (SANS). Patients had not previously received any
neuroleptic or antidepressant medication. Mean specific TRODAT-1
binding in the striatum did not differ significantly between the patient
and the age- and sex-matched control group (1.25 vs. 1.28). Variance
was significantly higher in the patient group. The data obtained with the
new ligand in first-episode, drug-naive schizophrenic patients are in line
with the PET results from the group of Laakso et al. in a comparable
patient sample. [99mTc]TRODAT-1 seems to be a valuable new SPECT-
ligand in the evaluation of the presynaptic site of the striatal
dopaminergic synapse in schizophrenia.
Keywords
schizophrenia, striatal dopamine transporter, first episode, drug-naive,
SPECT, [99mTc]TRODAT-1
Introduction
The role of the dopaminergic system in schizophrenia is still a
focus of discussion with regard to the etiology and pathogenesis of
the disease. Certainly, connotation has changed since the time of
the classical ‘dopamine hypothesis of schizophrenia’, once estab-
lished based on the data from Carlsson (Carlsson and Lindqvist,
1963). Using dopamine depletion with -methylparatyrosin, Abi-
Dargham and colleagues recently demonstrated that occupancy of
the postsynaptic striatal dopamine D2 receptor, by endogenous
dopamine is significantly higher in schizophrenic patients than in
healthy controls (Abi-Dargham et al., 2000). Together with data
from in vivo imaging protocols analysing the presynaptic
dopamine metabolism and release, e.g., the use of radiolabelled L-
dopa or amphetamin stimulation (Reith et al., 1994; Hietala et al.,
1995; Dao-Castellana et al., 1997; Breier et al., 1997, Laruelle et
al., 1997, Abi-Dargham et al., 1998; Lindstrom et al., 1999; Laru-
elle et al., 1999), there is an increasing amount of evidence for a
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‘hyperdopaminergic state’ or at least severe disturbances of
dopamine regulation in acute psychosis. However, the basic
mechanism of this process is not yet fully understood.
Theoretical and experimental cellular and animal work has
revealed that the presynaptic dopamine transporter (DAT) plays a
key role in regulating the dopamine (DA) content in the synaptic
cleft by transporting it into DA terminals, thereby gating signal
transduction by controlling the effective concentration of the neu-
rotransmitter available for postsynaptic receptor binding (Bannon
et al., 2000). The dopamine transporter is located on DA nerve ter-
minals and, in general, serves as a marker of DA nerve integrity.
DAT´s are expressed in a small number of neurons in the brain,
mainly in striatum and nucleus accumbens, but also in the globus
pallidus, cingulated cortex, olfactory tubercle, amygdala, and the
midbrain (Ciliax et al., 1995).
To date only a few imaging studies have dealt with the assess-
ment of the striatal presynaptic dopamine transporter in schizo-
phrenia, and the data are inconsistent. Laakso found no differences
in binding of the PET-ligand [18F]CFT in nine neuroleptic-naive
schizophrenic patients compared to age-matched healthy controls
(Laakso et al., 2000). In contrast, the group demonstrated a
significant decrease – compared to age-matched controls – of
DAT-binding of the same ligand in a group of eight stable, med-
icated, chronic schizophrenic patients (Laakso et al., 2001). Using
the single-photon emission computed tomography (SPECT-)
ligands [123I]-CIT and [123I]FP-CIT, neither Laruelle nor
Lavalaye found binding differences in neuroleptic-naive or treated
patients of different ages (Laruelle et al., 2000; Lavalaye et al.,
2001).
With respect to the inconsistency of the data, it is of especial
interest to analyse DAT-binding in schizophrenic patients with a
ligand that has different chracteristics than those of [18F]CFT- or
123I-labelled ones. Owing to its favourable imaging characteristics,
broad availability and cost efficiency, Technetium-99m [99mTc] is
the most-used radioisotope. Only recently, a tropane derivative,
TRODAT-1 [Ethanethiol, 2-((2(((3-(4-chlorophenyl)-8-methyl-8-
azabicyclo(3,2,1)oct-2-yl)methyl)(2-mercaptoethyl) amino) ethyl)
amino, (1R-exo-exo))-], was successfully labelled with [99mTc]
(Meegalla et al., 1997, 1998). [99mTc]TRODAT-1 has been charac-
terized as a reversible binding agent to the DAT (for rev, see Kung
2001). Valid biodistribution data and dosimetry of
[99mTc]TRODAT-1 are available (Mozley et al., 1998). Animal
data show a sensitive binding behaviour of TRODAT-1 to the
DAT, depending on the endogenous dopamine level: minor
changes induced by low doses of L-dopa, y-hydroxybutyrolactone
(GBL) or apomorphine did not change TRODAT-1 binding
whereas a high L-dopa dose and d-amphetamine reduced
TRODAT-1 binding significantly in a dose-dependent manner.
Additionally, pre-blocking of the DAT by CFT or
methylphenidate inhibited TRODAT-1 binding, also in a dose-
dependent manner (Dresel et al., 1998). In our laboratory, time
activity measurement was performed analysing TRODAT-1
binding behaviour to frontal, occipital, cerebellar cortex and stria-
tum within ten healthy volunteers (Fig. 1; La Fougère 2003).
Additionally, a study in 17 patients suffering from attention deficit
hyperactivity disorder (ADHD) before and after methylphenidate
treatment was performed demonstrating the usefulness of
[99mTc]TRODAT-1 to label specific changes in striatal DAT avail-
ability (Dresel et al., 2000). In schizophrenic patients, a first study
of Hsiao et al., did not demonstrate a significant difference of
TRODAT-1 binding compared to the control group (Hsiao et al.,
2003). Thus, [99mTc]TRODAT-1 is presumed to be a valid
SPECT-ligand with high specifity for DAT imaging, but to have
lower affinity than other SPECT-ligands such as -CIT or FP-CIT.
Although, TRODAT-1 measures may be sensitive to large
increases in synaptic dopamine, these are unlikely to be seen
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Figure 1 Time-activity curves of [99mTc]TRODAT-1 binding in 10 healthy volunteers; data from striatum and frontal, occipital and cerebellar cortex
(adapted from La Fougère, 2003)
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within schizophrenia considering the magnitude of change seen by
other investigators.
The aim of the present SPECT investigation was to compare
striatal DAT-binding of [99mTc]TRODAT-1 in first-episode, previ-
ously untreated patients with a diagnosis of schizophrenia and
age- and sex-matched healthy controls.
Methods
The SPECT investigation was approved by the ethics committee of
the LM-University of Munich, Germany and the local authorities of
radiation protection. The study was performed in accordance with
the ethical standards defined in the Declaration of Helsinki 1975,
revised in Hong Kong 1989. Following a detailed description of the
study, written informed consent was obtained from all subjects.
In this ongoing study, inpatients with a first diagnosis of para-
noid schizophrenia according to DSM-IV/ICD-10 criteria were
included in the first week after admission to hospital. In ten patients,
diagnosis was confirmed by the independent psychiatrist responsible
for the patient on ward after the end of treatment. Six males and
four females, mean age 34.9 years (34.912.11; range: 19 to 54),
were included for analyses of the [99mTc]TRODAT-1-SPECT. The
control group consisted of ten healthy subjects, six males and four
females, mean age 37.8 years (37.810.76; range: 21 to 53). On
the day of SPECT, psychopathology ratings, including Clinical
Gobla Impression (CGI), Global Assessment of Functioning (GAF),
Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syn-
drome Scale (PANSS) and Schedule for Assessment of Negative
Symptoms (SANS), were performed by an independent psychiatrist.
Patients underwent a routine laboratory analysis, electrocardiogram
(ECG) and structural magnetic resonance imaging (MRI). Concomi-
tant medication was restricted to zopiclon.
SPECT scanning was typically performed in the morning. The
procedure follows an established protocol (Dresel et al., 2000,
Krause et al., 2000; La Fougère 2003). In brief, 180 minutes after
radiotracer administration (740 MBq [99mTc]TRODAT-1), SPECT
acquisitions were performed over a period of 50 minutes on a triple
headed gamma camera (Picker, Cleveland, Ohio) equipped with
high resolution fan beam collimators. The acquisition parameters
included a 15% energy window centered on 140keV, a rotational
radius of 13cm or less, 120 projection angles over 360 degrees, and
a 128128 matrix with a pixel width of 2.11mm in the projection
domain. The projection images were reconstructed by filtered back
projection and filtered by a low pass filter. Chang’s first order
method was used for uniform attenuation correction. Images were
uniformly resliced by drawing a line connecting the anterior-most
aspect of the frontal pole to the posterior-most aspect of the occipi-
tal pole, which approximates the line connecting anterior and poste-
rior commissures (AC–PC line).
In order to assess specific tracer uptake in the striatum, we used
the region of interest (ROI) technique. In each patient, data were
evaluated in the two consecutive transverse slices showing the
highest tracer accumulation in the basal ganglia. The arithmetic
mean of these two slices was calculated. Mean specific activity in the
basal ganglia regions was calculated by subtracting the mean counts Figure 2 [99mTC]TRODAT-1 binding, one drug-naive schizophrenic
per pixel in the cerebellum as background (BKG) from the basal
ganglia region (STR) and dividing the results by the mean counts per
pixel in the background [(STR-BKG)/BKG]. Templates were used to
define the striatal ROI’s. The size and shape of the templates was
established and optimized using the data from the control group
(n10). For each individual patient, the templates were adjusted to
fit and corrected for anatomical differences in angle, size and dis-
tance between the interesting structures using an individual structural
MRI-scan by side. The non-specific background activity was esti-
mated by drawing a ROI around the cerebellum. The operator was
blind to the case. An example of a single case study using the
[99mTc]TRODAT-1)-SPECT technique is shown in Fig. 2. Data were
compared to the age-matched control group described above.
SPSS version 11.0 was used for statistical analysis of SPECT
and sociodemographic data. Student’s t-test was performed to
compare two independent groups, i.e., patients vs. controls. The
effect of the diagnosis (i.e., patients vs. healthy subjects) on
TRODAT-1-ligand binding was studied with a one-way analysis
of variance using age as the covariate (ANCOVA). Equality of
variances were tested using Levene’s test of equality of variances.
Continuous values were correlated using Pearson correlation coef-
ficients, whereby Spearman´s rho was calculated where necessary.
Differences were considered to be significant when p0.05.
Results
There was no significant difference between the patient and
control groups with respect to age (Students independent t-test 
 at LMU Muenchen on June 17, 2013jop.sagepub.comDownloaded from 
The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients 491
T value0.561, p0.58). Variance also did not differ
significantly (Levene test F value0.052, p0.82). The mean
duration of the patients´ illness was 9.710.3 months. None of the
patients had previously received neuroleptic or antidepressant treat-
ment (see Table 1 for detailed description of patients and controls).
The mean striatal TRODAT-1-binding ((STR-CER)/CER) in the
patient group was 1.250.33, range 0.71 to 1.63, vs. 1.280.09,
range 1.19 to 1.49, in the control group. Patients showed no signific-
ant difference in [99mTc]TRODAT-1 binding to the striatal DAT
compared to the control group (Students independent t-test T
value0.29, p0.78). Variance of the ligand binding differed sig-
nificantly (Levene test F value9.91, p0.006). (see Fig. 1:
[99mTc]TRODAT-1-binding of patient 3).
The ANCOVA of TRODAT-1 binding comparing the diagnosis
of both groups, with age as the covariate, showed a significant effect
of age on TRODAT-1 binding (F value10.10, df 1, p0.005),
but no significant interaction between age and diagnosis with
respect to the ligand binding in either group (F value0.59, df1,
p0.452). There was no significant gender effect, neither in the
whole group (F value0.137, df1, p0.72) or in each of the
two groups (F value0.00, df1, p0.988).
Analysis of the psychopathological assessment showed a mean
CGI score of 6.45 (range 5.5 to 7), and a mean GAF score in the
last year of 78 (range 90 to 60). Mean BPRS score was 73.2
(range 41 to 101), mean PANSS positive score 28.6 (range 21 to
39), mean PANSS negative score 25.2 (range 18 to 29), and mean
PANSS global score 60.2 (range 38 to 77). In the SANSS, the
mean score was 62.1 (range 35 to 86). There was no significant
correlation between any of the psychopathological rating scales
and the TRODAT-1-binding to the DAT.
As patients were admitted to hospital with a first diagnosis of a
paranoid syndrome according to the DSM-IV/ICD-10 criteria for
schizophrenia, we checked the diagnosis at the end of inpatient
treatment. Six patients fulfilled the criteria for paranoid and two
for disorganized psychosis and two were finally diagnosed as
schizoaffectively ill.
Discussion
Our data in first episode, drug-naive schizophrenic patients are in
line with the TRODAT-1-SPECT data in a comparable patient
group by Hsiao (Hsiao et al., 2003). The dopamine transporter
SPECT studies in these patients performed with other ligands such
as [123I]-CIT or [123I]FP-CIT also found no difference in ligand
binding compared to the control samples (Laruelle et al., 2000;
Lavalaye et al., 2001). The PET data from Laakso et al., who
analysed nine neuroleptic-naive schizophrenic patients compara-
ble to those in our group with respect to age and duration of
illness, did not show significant overall binding differences, too
(Laakso et al., 2000).
Thus, the imaging data confirm the established post mortem
results that there is no change of DAT density in schizophrenic
patients (Bannon et al., 2000), even though data from older and
neuroleptic-treated patients may not be comparable with ours from
first-episode and never-treated patients. Only a few post mortem
studies have demonstrated a significant reduction of DAT in schiz-
ophrenic patients (e.g., Dean and Hussain, 2001). These studies
used a different radioligand for DAT labelling compared to other
groups which did not find this difference (e.g., Knable et al.,
1994). So, these results will certainly have to be discussed with
special attention to methodological differences (Bannon et al.,
2001).
In an animal model of neonatal temporal limbic damage, which
is supposed to mimic developmental defects equivalent to those
postulated occurring in schizophrenia, Heinz and the group of
Weinberger could not demonstrate a change in DAT availability to
the SPECT ligand -CIT, although postsynaptic D2 receptor avail-
ability was significantly reduced (Heinz et al., 1999). So, evidence
is increasing, that there might be a striatal hyperdopaminergic
state bound to illness phases in schizophrenia, which is not based
on structural presynaptic defects, but may reflect a functional dys-
balance.
Those imaging studies that found a difference in presynaptic
dopamine activity in schizophrenic patients, e.g., after ampheta-
Table 1 Patients’ and healthy controls’ demographic and specific TRODAT-1 binding characteristics
Duration of [STR-BKG]/ Healthy [STR-BKG]/ 
Gender Age ICD-10 illness BKG control Gender Age BKG 
Patient m/f (years) diagnosis (months) TRODAT-1 person m/f (years) TRODAT-1
1 m 19 F20.0 1 1.63 1 m 21 1.49
2 m 20 F20.1 6 1.17 2 m 28 1.30
3 m 26 F20.1 3 1.27 3 m 32 1.34
4 m 32 F20.0 8 1.52 4 m 33 1.26
5 f 32 F25.0 6 1.54 5 f 34 1.21
6 f 34 F20.0 9 1.28 6 f 36 1.20
7 m 35 F20.0 6 1.51 7 m 39 1.25
8 m 45 F25.0 4 0.73 8 m 49 1.26
9 f 52 F20.0 36 1.10 9 f 53 1.27
10 f 54 F20.0 18 0.71 10 f 53 1.19
MeanSD 34.912.1 9.710.3 1.250.3 37.8  10.7 1.28  0.09G1
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mine stimulation, obviously demonstrated a difference rather in
function than in structural integrity as Laakso yet argued (Laakso
et al., 2000). Findings published recently by Laakso et al. reported
a decrease of DAT-ligand binding in clinically stable, medicated,
chronic schizophrenic patients. As the authors point out, these
findings may have to be interpreted in the context of disease pro-
gression or neuroleptic medication (Laakso et al., 2001). Contrar-
ily, Sjoholm et al. showed just recently in likewise chronic,
medicated schizophrenic patients, but in a small cohort (n 6) and
with the SPECT technique and -CIT, a significant increase of
DAT availability (Sjoholm et al., 2004). Besides the methodo-
logical differences, there might be patient group differences
regarding duration of disease, number, gender and neuroleptics
used. In any case, schizophrenic patients seem to differ with
respect to DAT availability at the beginning of disease compared
to the chronic, medicated state.
We did not find a significant interaction between the binding of
TRODAT-1 and one of the psychopathological ratings used. This
may be due to the small size of the patient group analysed,
however, it is in line with the two main imaging studies in this
field by Laakso and Lavalaye mentioned above. Both studies had
comparable sample sizes and neither detected significant correla-
tions between binding to the DAT of the applied radioligand and
the psychopathological rating scales.
An age-related decline of striatal DAT density has been
described in healthy humans, although data from in vivo imaging
studies differ with respect to characteristics and amount of the
decline depending on the ligand used. With TRODAT-1, Mozley
et al. found a nonlinear reduction of about 11% per decade until
what they call a ‘break point’ at the age of 36 (4). The decline is
reduced to about 3% in later life (Mozley et al., 1999). In our
sample, we also found a significant influence of age on TRODAT-
1-binding in both the patient and the age-matched healthy control
group. We cannot reach a final conclusion about the degree of age-
related vs. illness-related decline in our study due to the inhomo-
geneity of our patient group with respect to age – as this was not
the primary interest of our study – and the sample size, which was
too small to allow such a question to be answered. But we did not
find an effect of diagnosis on TRODAT-1 binding in the patient
group, so we may conclude that there is no illness specific change
in DAT density.
A gender effect of dopamine transporter density has been
described in animals (Rivest et al., 1995). Female rats show a
higher density of striatal DAT than males. In humans, a pro-
nounced heterogeneity of striatal DAT in healthy females was
found by Kuikka et al. (1997). In both our groups with six males
and four females, we did not find a gender influence in the whole
group or in the subgroups, respectively. This may happen by influ-
ence of the patient group – until now, sex differences with respect
to DAT in schizophrenic patients have not yet described. And our
group of healthy volunteers certainly is to small to detect the quite
discrete differences found by other groups (e.g., Lavalaye et al.,
2000; Mozley et al., 2001, Staley et al., 2001).
Besides its binding characteristics, [99mTc]TRODAT-1 opens a
further interesting field of SPECT technology: the labelling with
the radioisotope [99mTc] offers the possibility to use simultan-
eously a second, iodine-123-labelled ligand in addition to [99mTc].
Dual-isotope SPECT studies of the DAT using [99mTc]TRODAT-
1, with simultaneous assessment of the dopamine D2 receptor
using [123I]IBZM, have already been performed in baboons (Dresel
et al., 1999). These studies showed that the simultaneously
recorded images were comparable to those obtained on separate
days. Recently, a group from Taiwan presented data using
[99mTc]TRODAT-1 and [123I]IBZM in a 6-hydroxydopamine (6-
OHDA) animal model of Parkinson´s disease (Ma et al., 2002). In
monkeys, a significant reduction of TRODAT-1 binding in the
lesioned compared to the healthy animals was shown, while the
IBZM-binding to the D2-receptor remained unchanged (Ma et al.,
2002). And finally, the first dual isotope human study in schizo-
phrenic patients was published last year by Yang et al. (Yang et
al., 2004). Thus, it appears that a dual-isotope SPECT-technique
to perform simultaneous assessment of the pre- and postsynaptic
part of the dopaminergic synapse is available now. This technique
will further increase the possibilities of research with respect to
the measurement of interactions at the synaptic level in the normal
state, in illness, and after functional stimulation, and the influence
of specific treatment in humans in vivo.
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